Infliximab as a second-line therapy for children with refractory Kawasaki disease: A systematic review and meta-analysis of randomized controlled trials.

Suad Kabbaha Alyssa Milano Mamoon A Aldeyab Kristian Thorlund

Published in: British journal of clinical pharmacology (2022)

Moderate-certainty evidence indicates that infliximab may reduce the incidence of treatment resistance in children with refractory KD. However, the limited strength of evidence warrants further research.

Keyphrases

young adults
risk factors
high intensity